Eledon Pharmaceuticals Earnings Estimate
| ELDN Stock | USD 2.02 0.01 0.50% |
Eledon Pharmaceuticals Earnings Estimation Breakdown
The calculation of Eledon Pharmaceuticals' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Eledon Pharmaceuticals is estimated to be -0.235625 with the future projection ranging from a low of -0.3275 to a high of -0.18. Please be aware that this consensus of annual earnings estimates for Eledon Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.33 Lowest | Expected EPS | -0.18 Highest |
Eledon Pharmaceuticals Earnings Projection Consensus
Suppose the current estimates of Eledon Pharmaceuticals' value are higher than the current market price of the Eledon Pharmaceuticals stock. In this case, investors may conclude that Eledon Pharmaceuticals is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Eledon Pharmaceuticals' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2026 | Current EPS (TTM) | |
| 7 | 50.0% | 0.0 | -0.235625 | -1.3 |
Eledon Pharmaceuticals Earnings per Share Projection vs Actual
Actual Earning per Share of Eledon Pharmaceuticals refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Eledon Pharmaceuticals predict the company's earnings will be in the future. The higher the earnings per share of Eledon Pharmaceuticals, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Eledon Pharmaceuticals Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Eledon Pharmaceuticals, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Eledon Pharmaceuticals should always be considered in relation to other companies to make a more educated investment decision.Eledon Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Eledon Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
null | null | null | null | null | 0 | ||
2025-11-14 | 2025-09-30 | -0.2414 | -0.21 | 0.0314 | 13 | ||
2025-08-14 | 2025-06-30 | -0.22 | -0.13 | 0.09 | 40 | ||
2025-05-07 | 2025-03-31 | -0.3033 | -0.08 | 0.2233 | 73 | ||
2025-03-26 | 2024-12-31 | -0.3267 | -0.9456 | -0.6189 | 189 | ||
2024-11-07 | 2024-09-30 | -0.31 | -0.32 | -0.01 | 3 | ||
2024-08-19 | 2024-06-30 | -0.3 | -1.06 | -0.76 | 253 | ||
2024-06-20 | 2024-03-31 | -0.37 | -0.34 | 0.03 | 8 | ||
2024-03-28 | 2023-12-31 | -0.39 | -0.29 | 0.1 | 25 | ||
2023-11-09 | 2023-09-30 | -0.46 | -0.35 | 0.11 | 23 | ||
2023-08-10 | 2023-06-30 | -0.46 | -0.4 | 0.06 | 13 | ||
2023-05-11 | 2023-03-31 | -0.6 | -0.75 | -0.15 | 25 | ||
2023-03-30 | 2022-12-31 | -0.7 | -0.69 | 0.01 | 1 | ||
2022-11-14 | 2022-09-30 | -0.68 | -0.73 | -0.05 | 7 | ||
2022-08-11 | 2022-06-30 | -0.7 | -0.65 | 0.05 | 7 | ||
2022-05-12 | 2022-03-31 | -0.68 | -0.69 | -0.01 | 1 | ||
2022-03-24 | 2021-12-31 | -0.75 | -0.59 | 0.16 | 21 | ||
2021-11-11 | 2021-09-30 | -0.65 | -0.66 | -0.01 | 1 | ||
2021-08-12 | 2021-06-30 | -0.57 | -0.5 | 0.07 | 12 | ||
2021-05-13 | 2021-03-31 | -0.32 | -0.57 | -0.25 | 78 | ||
2021-03-30 | 2020-12-31 | -1.39 | -2.12 | -0.73 | 52 | ||
2020-11-16 | 2020-09-30 | -1.75 | -5.51 | -3.76 | 214 | ||
2020-08-14 | 2020-06-30 | -2.97 | -2.16 | 0.81 | 27 | ||
2020-05-15 | 2020-03-31 | -2.88 | -3.42 | -0.54 | 18 | ||
2020-03-17 | 2019-12-31 | -4.68 | -3.24 | 1.44 | 30 | ||
2019-11-13 | 2019-09-30 | -7.29 | -3.96 | 3.33 | 45 | ||
2019-08-13 | 2019-06-30 | -7.65 | -6.3 | 1.35 | 17 | ||
2019-05-14 | 2019-03-31 | -8.73 | -9.36 | -0.63 | 7 | ||
2019-03-28 | 2018-12-31 | -7.2 | -8.82 | -1.62 | 22 | ||
2018-11-13 | 2018-09-30 | -7.2 | -6.66 | 0.54 | 7 | ||
2018-08-07 | 2018-06-30 | -5.58 | -6.12 | -0.54 | 9 | ||
2018-05-11 | 2018-03-31 | -5.22 | -6.48 | -1.26 | 24 | ||
2017-08-09 | 2017-06-30 | -48.6 | -23.76 | 24.84 | 51 | ||
2017-05-03 | 2017-03-31 | -48.6 | -27.54 | 21.06 | 43 | ||
2017-03-03 | 2016-12-31 | -55.08 | -27.54 | 27.54 | 50 | ||
2016-11-03 | 2016-09-30 | -68.85 | -66.42 | 2.43 | 3 | ||
2016-08-04 | 2016-06-30 | -86.83 | -97.2 | -10.37 | 11 | ||
2016-05-10 | 2016-03-31 | -81.32 | -82.62 | -1.3 | 1 | ||
2016-03-10 | 2015-12-31 | -76.54 | -79.38 | -2.84 | 3 | ||
2015-11-10 | 2015-09-30 | -81.4 | -85.86 | -4.46 | 5 | ||
2015-08-12 | 2015-06-30 | -92.75 | -64.8 | 27.95 | 30 | ||
2015-05-12 | 2015-03-31 | -49.81 | -95.58 | -45.77 | 91 | ||
2015-03-12 | 2014-12-31 | -55.4 | -45.36 | 10.04 | 18 | ||
2014-11-10 | 2014-09-30 | -58.7 | -301.32 | -242.62 | 413 |
About Eledon Pharmaceuticals Earnings Estimate
The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Eledon Pharmaceuticals earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Eledon Pharmaceuticals estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Eledon Pharmaceuticals fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.| Last Reported | Projected for Next Year | ||
| Retained Earnings | -320 M | -304 M | |
| Earnings Yield | (0.21) | (0.22) | |
| Price Earnings Ratio | (4.97) | (5.22) |
Pair Trading with Eledon Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Eledon Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eledon Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Eledon Stock
Moving against Eledon Stock
| 0.57 | CDIOW | Cardio Diagnostics | PairCorr |
| 0.55 | VCYT | Veracyte | PairCorr |
| 0.44 | OSE | OSE Pharma SA | PairCorr |
| 0.34 | RAC | Race Oncology | PairCorr |
The ability to find closely correlated positions to Eledon Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Eledon Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Eledon Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Eledon Pharmaceuticals to buy it.
The correlation of Eledon Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Eledon Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Eledon Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Eledon Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eledon Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. To learn how to invest in Eledon Stock, please use our How to Invest in Eledon Pharmaceuticals guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Will Biotechnology sector continue expanding? Could Eledon diversify its offerings? Factors like these will boost the valuation of Eledon Pharmaceuticals. Projected growth potential of Eledon fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Eledon Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding Eledon Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects Eledon's accounting equity. The concept of intrinsic value - what Eledon Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Eledon Pharmaceuticals' price substantially above or below its fundamental value.
It's important to distinguish between Eledon Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Eledon Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Eledon Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.